Update on the combination effect of macrolide antibiotics in community-acquired pneumonia
M Emmet O'Brien1, Marcos I Restrepo2, Ignacio Martin-Loeches1
1Multidisciplinary Intensive Care Research Organization, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland.
Abstract:
Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated with improved treatment responses and patient outcomes. In the post-antibiotic era, much of the morbidity and mortality of CAP is as a result of the interaction between bacterial virulence factors and host immune responses. In patients with severe CAP, or who are critically ill, there is a lot of emerging observational evidence demonstrating improved survival rates when treatment using combination therapy with a β-lactam and a macrolide is initiated, as compared to other antibiotic regimes without a macrolide. Macrolides in combination with a β-lactam antibiotic provide broader coverage for the atypical organisms implicated in CAP, and may contribute to antibacterial synergism. However, it has been postulated that the documented immunomodulatory effects of macrolides are the primary mechanism for improved patient outcomes through attenuation of bacterial virulence factors and host systemic inflammatory responses. Despite concerns regarding the limitations of observational evidence and the lack of confirmatory randomized controlled trials, the potential magnitude of mortality benefits estimated at 20-50% cannot be overlooked. In light of recent data from a number of trials showing that combination treatment with a macrolide and a suitable second agent is justified in all patients with severe CAP, such treatment should be obligatory for those admitted to an intensive care setting.
Insights
Combination antibiotic therapy, including a macrolide, improves survival for severe community-acquired pneumonia (CAP). This approach is crucial for critically ill patients, offering significant mortality benefits.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Community-acquired pneumonia (CAP) is a major global cause of infectious disease mortality.
- The interaction between bacterial virulence and host immune responses significantly impacts CAP severity and outcomes.
- Emerging evidence suggests combination antibiotic therapy improves survival in severe CAP.
Purpose of the Study:
- To evaluate the efficacy of combination therapy (β-lactam and macrolide) versus other regimens for severe CAP.
- To explore the potential mechanisms, including immunomodulatory effects, behind improved outcomes with macrolide combination therapy.
- To determine if combination therapy with a macrolide is essential for all severe CAP patients, especially those in intensive care.
Main Methods:
- Review of observational evidence and recent trial data on antibiotic regimens for severe CAP.
- Comparison of survival rates between combination therapy (β-lactam + macrolide) and alternative antibiotic strategies.
- Analysis of potential benefits, including broader atypical organism coverage and antibacterial synergism.
Main Results:
- Observational data indicate improved survival rates with β-lactam and macrolide combination therapy in severe CAP.
- Macrolides may offer benefits through immunomodulation, attenuating virulence factors and systemic inflammation.
- Estimated mortality benefits range from 20-50%, highlighting the significance of this therapeutic approach.
Conclusions:
- Combination treatment with a macrolide and a β-lactam is justified for all severe CAP patients.
- This combination therapy should be considered obligatory for patients admitted to an intensive care setting.
- Further research, including randomized controlled trials, is warranted to confirm these findings.
More Related Videos
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:25Mechanism of Antibiotic Resistance in MRSA
01:14Atypical Pneumonia
01:25Clinical Significance of Antibiotic Resistance
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Inhibitors of Bacterial Protein Synthesis